Telescope Innovations Appoints Vaso Vlachos as Chief Operating Officer
Telescope Innovations (OTCQB: TELIF), a leader in intelligent automation platforms for chemical process development, has appointed Vaso Vlachos as Chief Operating Officer. With over 20 years of experience in automation and analytical technology for biopharmaceutical and chemical industries, Vlachos joins from Mettler-Toledo AutoChem where she served as Global Head of Real-Time Analytics.
The company's DirectInject-LC product has doubled in sales opportunities in Q3 2025 compared to Q3 2024, with operations expanding from North America to Europe, Japan, and China. Telescope is also advancing Self-Driving Lab deployments with partners like Pfizer and developing lithium refinement technologies.
Additionally, the company granted 518,140 stock options to employees and consultants, exercisable at $0.43 until September 2, 2030.
Telescope Innovations (OTCQB: TELIF), azienda leader nelle piattaforme di automazione intelligente per lo sviluppo di processi chimici, ha nominato Vaso Vlachos come Chief Operating Officer. Con oltre 20 anni di esperienza in automazione e tecnologie analitiche per le industrie biofarmaceutica e chimica, Vlachos arriva da Mettler‑Toledo AutoChem, dove ricopriva il ruolo di Global Head of Real‑Time Analytics.
Le opportunità di vendita del prodotto DirectInject‑LC sono raddoppiate nel terzo trimestre 2025 rispetto al terzo trimestre 2024, con l’espansione delle operazioni dal Nord America all’Europa, al Giappone e alla Cina. Telescope sta inoltre portando avanti implementazioni di Self‑Driving Lab con partner come Pfizer e sviluppando tecnologie per la raffinazione del litio.
Inoltre, la società ha assegnato 518.140 opzioni su azioni a dipendenti e consulenti, esercitabili a $0,43 fino al 2 settembre 2030.
Telescope Innovations (OTCQB: TELIF), líder en plataformas de automatización inteligente para el desarrollo de procesos químicos, ha nombrado a Vaso Vlachos como Chief Operating Officer. Con más de 20 años de experiencia en automatización y tecnología analítica para las industrias biofarmacéutica y química, Vlachos se incorpora desde Mettler‑Toledo AutoChem, donde fue Global Head of Real‑Time Analytics.
Las oportunidades de venta del producto DirectInject‑LC se han duplicado en el tercer trimestre de 2025 respecto al tercer trimestre de 2024, con la expansión de operaciones desde Norteamérica a Europa, Japón y China. Telescope también está avanzando en despliegues de Self‑Driving Lab con socios como Pfizer y desarrollando tecnologías de refinación de litio.
Además, la compañía otorgó 518.140 opciones sobre acciones a empleados y consultores, ejercitables a $0.43 hasta el 2 de septiembre de 2030.
Telescope Innovations (OTCQB: TELIF), 화학 공정 개발을 위한 지능형 자동화 플랫폼의 선두업체가 Vaso Vlachos를 최고운영책임자(Chief Operating Officer)로 임명했습니다. 바이오제약 및 화학 산업용 자동화와 분석 기술 분야에서 20년 이상의 경력을 쌓은 Vlachos는 실시간 분석(Global Head of Real‑Time Analytics) 책임자로 재직한 Mettler‑Toledo AutoChem에서 합류했습니다.
회사 제품인 DirectInject‑LC의 영업 기회는 2025년 3분기에 2024년 3분기 대비 두 배로 증가했으며, 북미에서 유럽, 일본, 중국으로 운영을 확장했습니다. Telescope는 또한 Pfizer와 같은 파트너와 함께 Self‑Driving Lab 배치를 진행 중이며 리튬 정제 기술도 개발하고 있습니다.
또한 회사는 직원 및 컨설턴트에게 518,140주 상당의 스톡 옵션을 부여했으며, 이는 $0.43에 2030년 9월 2일까지 행사할 수 있습니다.
Telescope Innovations (OTCQB: TELIF), leader des plateformes d’automatisation intelligente pour le développement de procédés chimiques, a nommé Vaso Vlachos au poste de Chief Operating Officer. Forte de plus de 20 ans d’expérience en automatisation et technologies analytiques pour les industries biopharmaceutique et chimique, Vlachos rejoint l’entreprise depuis Mettler‑Toledo AutoChem, où elle était Global Head of Real‑Time Analytics.
Les opportunités de vente du produit DirectInject‑LC ont doublé au troisième trimestre 2025 par rapport au troisième trimestre 2024, avec une expansion des opérations de l’Amérique du Nord vers l’Europe, le Japon et la Chine. Telescope fait également progresser les déploiements de Self‑Driving Lab avec des partenaires comme Pfizer et développe des technologies de raffinage du lithium.
Par ailleurs, la société a accordé 518 140 options d’achat d’actions à des employés et consultants, exerçables à 0,43 $ jusqu’au 2 septembre 2030.
Telescope Innovations (OTCQB: TELIF), ein führendes Unternehmen für intelligente Automatisierungsplattformen zur Entwicklung chemischer Prozesse, hat Vaso Vlachos als Chief Operating Officer berufen. Vlachos verfügt über mehr als 20 Jahre Erfahrung in Automatisierungs- und Analysetechnologien für die Biopharma- und Chemieindustrie und kommt von Mettler‑Toledo AutoChem, wo sie als Global Head of Real‑Time Analytics tätig war.
Die Verkaufschancen für das Produkt DirectInject‑LC haben sich im dritten Quartal 2025 im Vergleich zum dritten Quartal 2024 verdoppelt; die Aktivitäten wurden von Nordamerika nach Europa, Japan und China ausgeweitet. Telescope treibt zudem Einsätze von Self‑Driving Labs mit Partnern wie Pfizer voran und entwickelt Technologien zur Lithium‑Veredelung.
Darüber hinaus gewährte das Unternehmen 518.140 Aktienoptionen an Mitarbeiter und Berater, ausübbar zu $0,43 bis zum 2. September 2030.
- None.
- Previous COO Jeff Sherman stepping down to advisory role
Vancouver, British Columbia--(Newsfile Corp. - September 2, 2025) - Telescope Innovations Corp. (CSE: TELI) (OTCQB: TELIF) (FSE: J4U) ("Telescope Innovations", "Telescope", or the "Company"), a leader in intelligent automation platforms for accelerating chemical process development, is pleased to announce the appointment of Vaso Vlachos as Chief Operating Officer (COO), effective immediately.
Ms. Vlachos is a proven leader with over 20 years of experience managing automation and analytical technology offerings for the biopharmaceutical and chemical industries. Her background spans sales & marketing, operations, quality, and innovation management. Most recently, she was the Global Head of Mettler-Toledo AutoChem's Real-Time Analytics ("RTA") business. She also previously steered the market development and commercialization of Mettler-Toledo's EasySampler™ probe, which has achieved long-lived, multi-year adoption by the pharmaceutical industry, integration with major lab instrument partners, and successfully developed and maintained a global distribution a decade after its launch. The EasySampler probe is also a key component of Telescope's DirectInject-LC™ product.
POSITIONING TO SCALE TELESCOPE'S ONLINE ANALYTICS BUSINESS
Telescope's first commercial product, DirectInject-LC™ has doubled in sales opportunities in its third fiscal quarter of 2025 compared to Q3, 2024, and commercial operations have expanded from the US and Canada to Europe, Japan, and China. Ms. Vlachos' experience in global product integration with sales and services strengthens Telescope's ability to grow both its installation base and bolster recurring revenue streams.
EXPANDING OPPORTUNITES IN SELF-DRIVING LABS
Beyond DirectInject-LC™, Telescope is advancing Self-Driving Lab ("SDL") deployments with leading partners, including Pfizer. Ms. Vlachos' track record aligning product, software, and field organizations will support efficient delivery and lifecycle management as SDL programs move from pilots to broader deployment.
STRENGTHENING CRITICAL MINERALS INITIATIVES
Telescope has advanced the commercial readiness of two proprietary lithium refinement technologies from R&D to lab piloting and customer sampling. Ms. Vlachos' operations leadership will focus on partner integration and scale-up readiness across these programs.
EXECUTIVE PERSPECTIVES
"Ms. Vlachos brings exactly the kind of hands-on, market-connected operating leadership we need as we scale DirectInject-LC™ globally and execute on SDL and process development opportunities. Her experience building world-class analytics and technology businesses maps directly onto Telescope's next stage," said Henry Dubina, CEO & Chairman. "On behalf of Telescope, I would also like to thank Dr. Jeff Sherman for his leadership as COO over the past few years. I am pleased to announce that he will continue to support Telescope in an advisory capacity, ensuring continuity as we expand our operations and pursue new opportunities."
"I'm excited to join a team that's converting deep chemistry and automation expertise into real customer value," said Vaso Vlachos. "Our focus is operational excellence, ensuring every installation delivers measurable gains in data quality, throughput, and time-to-decision for our customers."
The Company also announces that it has granted incentive stock option in the total amount of 518,140 options to 1 Consultant and 5 Employees of the Company in accordance with the Company's Equity Incentive Plan. The option vest according to the Company's Equity Incentive Plan and are exercisable to acquire common shares of the Company at a price of
About Telescope Innovations
Telescope Innovations is a chemical technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industry. The Company builds and deploys new enabling technologies including flexible robotic platforms and artificial intelligence software that improves experimental throughput, efficiency, and data quality. Our aim is to bring modern chemical technology solutions to meet the most serious challenges in health and sustainability.
On behalf of the Board,
Telescope Innovations Corp.
Henry Dubina, Chief Executive Officer
E: hdubina@telescopeinn.com
Forward-Looking Information
Forward-looking information is based on a number of opinions, assumptions and estimates that, while considered reasonable by the Company as of the date of this news release, are subject to known and unknown risks, and uncertainties that may cause the actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking information.
Forward-looking statements in this document include statements around the scale-up of the DirectInject-LC™ business, the progression of Telescope's SDL and lithium programs, the impact and customer value of Telescope's technology, and all other statements that are not statements of historical fact.
The forward-looking statements contained in this news release are made as of the date of this news release, and the Company expressly disclaims any obligation to update or alter statements containing any forward-looking information, or the factors or assumptions underlying them, whether as a result of new information, future events or otherwise, except as required by law.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/264650
FAQ
Who is the new COO of Telescope Innovations (TELIF)?
What is Telescope Innovations' (TELIF) main product performance in Q3 2025?
What stock options did Telescope Innovations (TELIF) grant in September 2025?
What are Telescope Innovations' (TELIF) key business areas in 2025?
What happened to Telescope Innovations' previous COO?
